PMID: 11934387Apr 6, 2002Paper

Cytogenetic analysis in 139 Tunisian patients with de novo acute myeloid leukemia

Annales de génétique
Halima Sennana SendiAli Saad

Abstract

This paper presents the results of a cytogenetic analysis in 139 Tunisian patients with de novo acute myeloid leukemia (AML), including 27 children aged 1-15 years and 112 adults. Mean age was 32 (range 1-75) and the M/F ratio was 1.43. Of our patients, 45% had apparently normal karyotypes. Acquired chromosome aberrations were found in 77 (55% ) patients. t(8;21) was identified in 27 patients (19%); t(15;17) in 13 patients (9%); deletion 7q or monosomy 7 in seven patients (5%); +8 in seven patients (5%); abnormal 16 in four patients (3%); 11q23 rearrangements in two patients (2%) and del(5q), in one patient (1%). The remaining 16 patients had miscellaneous clonal abnormalities. Specific translocations associated with the FAB type were found: t(8;21) with AML2 and t(15;17) with AML3. We concluded that our study in a Tunisian population confirmed the relation between some specific abnormalities and the FAB classification. We found a higher incidence for t(8;21) than usually described.

Citations

Dec 8, 2009·Cancer Genetics and Cytogenetics·Seung Hwan OhJeong Nyeo Lee
Sep 15, 2007·Cancer Genetics and Cytogenetics·Achandira Muthappa UdayakumarJohn Alexander Raeburn
Oct 3, 2006·Cancer Genetics and Cytogenetics·Tor OnstenGiorgio Paskulin
Mar 7, 2008·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Suheyla Uyar BozkurtTulay Tecimer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.